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Summary objective
Oral Candidiasis is the most common HIV related oral
lesion. Most patients are infected with a strain originally
present as a commensal of the oral cavity. The chronic use
of antifungal agents, in the treatment of candidiasis mainly
in HIV/AIDS patients leads to the selection of strain resis-
tant to this therapy. The objective of this study was to
evaluate the in vitro susceptibility of Candida albicans to
commonly used antifungal agents in Ethiopia.
Methods
In vitro susceptibility tests were performed using the
broth microdilution method following the National Com-
mittee for Clinical Laboratory Standards (NCCLS) M27-
A guidelines. Data were then analyzed using SPSS for
windows version 16.0. Tests of proportions were done
with Chi-Square, and a p value of <0.05 was considered
as statistically significant.
Results
A total of 42 oral C.albicans isolates from HIV-infected
patients were included in this study. Forty one (97.7%) of
all isolates were determined fully susceptible to ampho-
tericin B, 40 (95.3%) to nystatin, and 39 (92.9%) to keto-
conazole and miconazole. On the other hand, the isolates
showed highest rates of resistance against fluconazole
(11.9%) relatively. There was little difference in the anti-
fungal susceptibilities of C.albicans isolated from patients
who had a history of previous antifungal therapy
c o m p a r e dw i t ht h o s ew h oh a dn o tr e c e i v e da n t i f u n g a l
treatment.
Conclusion
The in vitro antifungal susceptibility testing of C.albicans
in this study showed relatively high resistance to com-
monly used azoles. As with the prescribing of any antimi-
crobial agent, the use of a systemic antifungal drug must
be justified. Efforts must be maintained to avoid inap-
propriate or unnecessary prescribing of these antifungal.
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